Zygrel Tablets / Film-coated

Clopidogrel
75mg
Oman Pharmaceutical Products
Pack size 28's (14's Blister x 2)
Dispensing mode POM
Source OMAN
AgentMuscat Pharmaceutical Trading L.L.C.
Retail Price 122.00 AED

Indications

Zygrel Tablets / Film-coated is used for: Coronary Artery Disease, Acute coronary syndrome, Myocardial infarction, Peripheral vascular disease, Cerebrovascular disease, Atherosclerosis, Thromboembolic disorders, Unstable angina, Stroke

Adult Dose

Oral Prophylaxis of thromboembolic disorders, Recent MI, Stroke, or Established Peripheral Arterial Disease, Coronary Artery Disease Adult: 75 mg once daily. Acute coronary syndrome Adult: For ST-elevation MI: In combination w/ aspirin: 75 mg once daily. <75 years 300 mg loading dose followed by 75 mg for 14 days up to 12 months (if no bleeding) Concomitant therapy with aspirin: Administer in combination with aspirin 75-325 mg qDay with or without thrombolytics >75 years No loading dose 75 mg for 14 days up to 12 months (if no bleeding) For unstable angina, non-ST-elevation MI: In combination w/ aspirin: Initially, 300 mg loading dose, followed by 75 mg once daily for up to 12 mth. Hepatic impairment: Use caution; experience limited

Child Dose

Renal Dose

Renal impairment: Dose adjustment not necessary

Administration

May be taken with or without food.

Contra Indications

Hypersensitivity. Active pathological bleeding. admin within 7 days after MI and ischaemic stroke, coagulation disorders. Lactation.

Precautions

Patients at risk of increased bleeding from trauma, surgery, or other pathological conditions; ulcer; renal and hepatic impairment; history of bleeding or haemostatic disorders. Pregnancy. Lactation: Not known whether drug is excreted in breast milk; not recommended

Pregnancy-Lactation

Pregnancy Available data from cases reported over two decades in published literature and postmarketing surveillance have not identified any drug-associated risks for major birth defects or miscarriage; there are risks to pregnant woman and fetus associated with myocardial infarction and stroke Myocardial infarction and stroke are medical emergencies; therapy for pregnant woman should not be withheld because of potential concerns regarding effects of clopidogrel on the fetus Labor or delivery Therapy during labor or delivery will increase risk of maternal bleeding and hemorrhage; avoid neuraxial blockade during clopidogrel use because of risk of spinal hematoma; when possible, discontinue therapy 5-7 days prior to labor, delivery, or neuraxial blockade There are no data on presence of drug in human milk or effects on milk production; no adverse effects on breastfed infants observed during lactation in a small number of postmarketing cases; studies in rats have shown that clopidogrel and/or its metabolites are present in milk; when a drug is present in animal milk, it is likely that the drug will be present in human milk; consider developmental and health benefits of breastfeeding along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from drug or underlying maternal condition

Interactions

Co-admin with NSAIDs may increase the risk of stomach and intestinal bleeding. High-dose clopidogrel may lead to increased warfarin levels thus increasing the risk of bleeding. High-dose clopidogrel may also inhibit P450 (2C9), thus interfering with the metabolism of phenytoin, tamoxifen, torasemide, fluvastatin and some NSAIDs. Avoid c

Adverse Effects

Side effects of Clopidogrel : 1-10% Upper respiratory tract infection (8.7%), Chest pain (8.3%), Headache (7.6%), Flulike syndrome (7.5%), Arthralgia (6%), Pain (6%), Dizziness (6%), Diarrhea (4.5%), Rash (4.2%), Rhinitis (4.2%), Depression (3.6%), Urinary tract infection (3.1%) <1% Severe neutropenia, Thrombotic thrombocytopenic purpura, Acute liver failure, Aplastic anemia, Hypotension, Hepatitis, Myalgia, Eczema, Erythema, Agranulocytosis Potentially Fatal: Bleeding disorders including GI and intracranial haemorrhage. Blood dyscrasias.

Mechanism of Action

Clopidogrel inhibits adenosine diphosphate (ADP) from binding to its receptor sites on the platelets and subsequent activation of glycoprotein GP IIb/IIIa complex thus preventing fibrinogen binding, platelet adhesion and aggregation.

Note

Zygrel 75mg Tablets / Film-coated manufactured by Oman Pharmaceutical Products. Its generic name is Clopidogrel. Zygrel is availble in United Arab Emirates. Farmaco UAE drug index information on Zygrel Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.

Some other brands of Clopidogrel :

Tablets / Film-coated
Antiplex 75mg
Dar Al Dawa Development & Investment Co. Ltd.
Tablets / Film-coated
Ceruvin 75mg
SUN PHARMACEUTICAL INDUSTRIES LTD
Tablets / Film-coated
Clopacin 75mg
Acino Pharma AG
Tablets / Film-coated
Clopidocor 75mg
SANDOZ PHARMACEUTICALS GmbH
Tablets / Film-coated
Clopigen 75mg
Nexgen Pharma FZ LLC